• Function as pharmacology core team representative for antiviral drug discovery programs. • Manage a team of four scientists responsible for the development and execution of biochemical and biophysical assays to support infectious disease and neuroscience programs. • Collaborate with CRO for assay support

Responsible for the generation of hit finding strategies with project teams from all therapeutic areas and management of a team of scientists on the execution of biochemical and cellular uHTS screens. Introduced, integrated and lead mass spectrometry-based screening activities within the department. • Function as screening point of contact and collaborate with cross-functional teams to generate uHTS screening strategies for programs from multiple therapeutic areas across the network. Support the team through delivery of a uHTS hit package and hit follow up.• Responsible for the management and growth of a team of six scientists on the development and implementation of assays to interrogate a 3 million member compound library.• Develop biochemical and cell-based assays and miniaturize them to 1536 or 3456-well plate formats for multiple target classes (i.e. kinases, proteases, protein-protein interactions, receptors) utilizing different assay formats (i.e. ELISA, TR-FRET, AlphaScreen, SPA, prompt fluorescence, luminescence).• Lead mass spectrometry-based screening effort in high throughput screening center of excellence. Identified the optimal equipment (Agilent RapidFire) then developed and implemented related workflows to integrate with site infrastructure. The platform is integral in reducing false positives delivered to the project teams and enabling challenging targets. • Managed implementation of Corning Epic system for biophysical measurements and aggregation studies

Responsible for the generation of hit finding strategies with project teams from all therapeutic areas and management of a team of scientists on the execution of biochemical and cellular uHTS screens. Introduced, integrated and lead mass spectrometry-based screening activities within the department. • Function as screening point of contact and collaborate with cross-functional teams to generate uHTS screening strategies for programs from multiple therapeutic areas across the network. Support the team through delivery of a uHTS hit package and hit follow up.• Responsible for the scientific management and of a team of five to six scientists on the development and implementation of assays to interrogate a 3 million member compound library.• Develop biochemical and cell-based assays and miniaturize them to 1536 or 3456-well plate formats for multiple target classes (i.e. kinases, proteases, protein-protein interactions, receptors) utilizing different assay formats (i.e. ELISA, TR-FRET, AlphaScreen, SPA, prompt fluorescence, luminescence).• Lead mass spectrometry-based screening effort in high throughput screening center of excellence. Identified the optimal equipment (Agilent RapidFire) then developed and implemented related workflows to integrate with site infrastructure. The platform is integral in reducing false positives delivered to the project teams and enabling challenging targets.

Responsible for the generation of hit finding strategies with project teams from all therapeutic areas and management of a team of scientists on the execution of biochemical and cellular uHTS screens. Introduced, integrated and lead mass spectrometry-based screening activities within the department. • Function as screening point of contact and collaborate with cross-functional teams to generate uHTS screening strategies for programs from multiple therapeutic areas across the network. Support the team through delivery of a uHTS hit package and hit follow up.• Responsible for the scientific management and growth of a team of scientists on the development and implementation of assays to interrogate a 3 million member compound library.• Develop biochemical and cell-based assays and miniaturize them to 1536 or 3456-well plate formats for multiple target classes (i.e. kinases, proteases, protein-protein interactions, receptors) utilizing different assay formats (i.e. ELISA, TR-FRET, AlphaScreen, SPA, prompt fluorescence, luminescence).• Lead mass spectrometry-based screening effort in high throughput screening center of excellence. Identified the optimal equipment (Agilent RapidFire) then developed and implemented related workflows to integrate with site infrastructure. The platform is integral in reducing false positives delivered to the project teams and enabling challenging targets.

• Function as people manager and scientific manager for a team of six scientists.• Develop and miniaturize biochemical and cell-based assays to 1536 or 3456-well plate formats for multiple target classes (i.e. kinases, proteases, protein-protein interactions, receptors) utilizing different assay formats (i.e. ELISA, HTRF, AlphaScreen, SPA, prompt fluorescence, luminescence).• Developed and implemented a novel lead optimization approach that received funding through a MRL Blue Sky idea competition • Utilize Surface Plasmon Resonance (Biacore) to screen the Merck Fragment Library against multiple targets as well as an orthogonal platform to follow up HTS hits

Responsible for bringing in the required equipment and evaluating the applicability of activity-based protein profiling to drug discovery programs.• Set up platform and evaluate the applicability of activity-based proteomics to internal programs • Designed and synthesized fluorescent activity-based probes for chemical proteomics.

Responsible for the development of assays and novel applications for an affinity selection/mass spectrometry (AS/MS) small molecule screening platform. Transitioned from an individual contributor to a manager of a group of protein biochemists responsible for collaborating with program teams and external collaborators. • Responsible for developing methods for screening protein target from multiple therapeutic areas against 200,000 to 400,000 compounds with affinity selection/mass spectrometry (AS/MS).• Designed and developed novel applications for affinity selection screening platform to address program specific problems such as selectivity, rank ordering of compounds, mode of binding, and substrate competition.• Executed collaboration between Merck and the laboratory of Professor David MacMillan of Princeton University that combined AS/MS with organo-cascade catalysis.• Responsible for people management and technical management of a research team. • Involved in initial set up, troubleshooting, and proof of concept experiments of affinity selection screening.

Responsible for the generation and execution of hit finding strategies with project teams from all therapeutic areas and management of a team of scientists on the execution of biochemical and cellular uHTS screens. Introduced, integrated and lead mass spectrometry-based screening activities within the department. • Function as screening point of contact and collaborate with multiple cross-functional teams to generate uHTS screening strategies for programs from diverse therapeutic areas across the network. Support the team through delivery of a uHTS data package and hit follow up.• Responsible for the management and growth of a team of six scientists on the development and implementation of assays to interrogate a 3 million member compound library.• Develop biochemical and cell-based assays and miniaturize them to 1536 or 3456-well plate formats for multiple target classes (i.e. kinases, proteases, protein-protein interactions, receptors) utilizing different assay formats (i.e. ELISA, TR-FRET, AlphaScreen, SPA, prompt fluorescence, luminescence).• Lead mass spectrometry-based screening effort in high throughput screening center of excellence. Identified the optimal equipment (Agilent RapidFire) then developed and implemented related workflows to integrate with site infrastructure. The platform is integral in generating label-free assays to reduce false positives delivered to the project teams and to enable challenging targets. • Managed implementation of Corning Epic system for biophysical measurements and aggregation studies.• Developed novel assay platform for monitoring zymogen activation.• In combination with internal team and external partner, developing new technologies for high throughput monitoring of cell permeability for therapeutic peptides.• Promoted to Principal Scientist in January 2015.